Harpoon Therapeutics (HARP) Stock Price, News & Analysis

Company Overview

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. 

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

Written by Jeffrey Neal Johnson

Key Stats

• Today's Range: $23.01 to $23.01
• 50-Day Range: $22.34 to $23.01
• 52-Week Range: $3.11 to $23.21
• Volume: N/A
• Average Volume: 1.52 million shs
• Market Capitalization: $389.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Hold

Harpoon Therapeutics Stock Analysis - MarketRank™

Harpoon Therapeutics scored higher than 18% of companies evaluated by MarketBeat, and ranked 911th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Harpoon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Harpoon Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Harpoon Therapeutics are expected to decrease in the coming year, from ($1.49) to ($4.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Harpoon Therapeutics has a P/B Ratio of 14.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HARP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harpoon Therapeutics does not currently pay a dividend.

Dividend Growth

Harpoon Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.61

Short Interest

There is no current short interest data available for HARP.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harpoon Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.00% of the stock of Harpoon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.01% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HARP Stock Analysis - Frequently Asked Questions

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its quarterly earnings results on Monday, March, 27th. The company reported ($5.50) earnings per share for the quarter, missing analysts' consensus estimates of ($4.70) by $0.80. The company earned $4.09 million during the quarter, compared to analysts' expectations of $11.06 million. Harpoon Therapeutics had a negative net margin of 81.68% and a negative trailing twelve-month return on equity of 893.55%.

When did Harpoon Therapeutics' stock split?

Harpoon Therapeutics's stock reverse split before market open on Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Harpoon Therapeutics IPO?

Harpoon Therapeutics (HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Harpoon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 3/27/2023
• Today: 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:HARP
• CUSIP: N/A
• CIK: 1708493
• Web: www.harpoontx.com
• Phone: (650) 443-7400
• Fax: N/A
• Employees: 53
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.00
• High Stock Price Target: $23.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: 0.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($8.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-67,730,000.00
• Net Margins: -81.68%
• Pretax Margin: -81.67%
• Return on Equity: -893.55%
• Return on Assets: -45.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.89
• Quick Ratio: 1.89

Sales & Book Value

• Annual Sales: $37.34 million
• Price / Sales: 10.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.63 per share
• Price / Book: 14.12

Miscellaneous

• Outstanding Shares: 16,932,000
• Free Float: 14,054,000
• Market Cap: $389.61 million
• Optionable: Optionable
• Beta: 2.11